Skip to main content
. Author manuscript; available in PMC: 2022 Feb 5.
Published in final edited form as: Cancer Treat Res Commun. 2018 Apr 23;16:1–8. doi: 10.1016/j.ctarc.2018.04.004

Table 3:

Health-related quality of life among participants (SF-12)*

Intervention Control Between
group
p-values
Mean (±SD)
(N)		 Change
from
Baseline
Mean (±SD)		 within
group
p-
values		 Mean (±SD) (N) Change
from
Baseline
Mean
(±SD)		 within
group
p-values
*PCS T1 (day of screen) 48.1 (±9.8) (7) -- -- 45.8 (±10.2) (8) -- -- --
T3 (3mo post-screen) 46.3 (±8.1) (7) 1.2 (±8.8) 0.76 44.9 (±11.1) (8) −1.0 (±10.0) 0.79 0.69
T4 (7mo post-screen) 37.6 (±12.9) (6) −7.8 (±7.7) 0.09 48.2 (±6.9) (7) 0.1 (±8.0) 0.96 0.12
**MCS T1 (day of screen) 54.4 (±8.2) (7) -- -- 50.9 (±10.6) (8) -- -- --
T3 (3mo post-screen) 53.2 (±10.7) (7) 0.5 (±11.4) 0.92 49.4 (±8.6) (8) −1.5 (±11.3) 0.71 0.75
T4 (7mo post-screen) 52.4 (±6.1) (6) 0.1 (±9.9) 0.98 42.5 (±12.6) (7) −7.2 (±16.8) 0.30 0.40
*

Physical Composite Score

**

Mental Composite Score

Range 0-100; higher score=better physical and psychological functioning; >50=above average health status

*

Only assessed at T1, T3, and T4